Abeid Athman (Omar). (@bin_abeid) 's Twitter Profile
Abeid Athman (Omar).

@bin_abeid

Clinical Oncologist at @KUTRRH.
Fellow at European School of Oncology @ESOncology and @IEO. ASCO24 IDEA Awardee. Proud Kilifornian

ID: 325190920

calendar_today27-06-2011 21:57:40

5,5K Tweet

2,2K Followers

958 Following

Abeid Athman (Omar). (@bin_abeid) 's Twitter Profile Photo
Abeid Athman (Omar).
@bin_abeid

2 months ago

ER-low (ER =1-9%) behaves more or less as TNBC. The PROMENADE RWD french trial shows that the addition of neoadjuvant Pembrolizumab in ER-LOW improves pCR using the KN522 regime. #ESMO2024 #ESMO24 OncoAlert Paolo Tarantino Sara Tolaney ESMO - Eur. Oncology Erika Hamilton, MD

ER-low (ER =1-9%) behaves more or less as TNBC. The PROMENADE RWD french trial shows that the addition of neoadjuvant Pembrolizumab in ER-LOW improves pCR using the KN522 regime. #ESMO2024 #ESMO24 <a href="/OncoAlert/">OncoAlert</a> <a href="/PTarantinoMD/">Paolo Tarantino</a> <a href="/stolaney1/">Sara Tolaney</a> <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/ErikaHamilton9/">Erika Hamilton, MD</a>